Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan

There have been significant advances in the early detection and treatment of cancer, which have led to improvements in overall survival rates in general patient populations over several decades [1]. However, the clinical outcomes of adolescent and young adult (AYA) patients, defined as those between the ages of 15 to 39, with cancer have not improved [1‐4]. One explanation for this is that, to date, little attention and few resources have been devoted to studying the incidence, biology, and treatment outcomes in AYA patients with cancer [5].

AYA patients with cancer are predominantly afflicted by lymphoma, melanoma, testicular cancer, sarcoma, thyroid cancer, leukemia, and breast cancer [5]. Sarcomas comprise up to 6% of total malignancies in AYAs and represent one of the most common types of cancer in this population [5]. However, sarcoma is generally a rare disease, and its estimated total crude incidence rate in Europe is 5.6 per 100,000 individuals per year [6]. A few previous studies have investigated the clinical outcomes of AYAs with bone sarcoma using nationwide or large databases with sufficient numbers of patients. However, most previous studies were based on data derived from small numbers of cases, and those with larger sample sizes have only analyzed a few disease-related factors [7‐11].

In Japan, no studies on the epidemiology and clinical outcomes of AYA patients with sarcoma compared with patients diagnosed at other ages have been conducted because of the lack of a suitable database. In 2014, the Bone and Soft Tissue Tumor (BSTT) registry—a nationwide organ-specific cancer registry for bone and soft tissue tumors in Japan—became available for the purposes of clinical research, enabling a large-scale nationwide epidemiological investigation of AYA patients with sarcoma.

The aims of the present study were: 1) to determine survival rates of bone sarcoma among AYAs in Japan (for comparison with other age groups), and 2) to establish whether belonging to the AYA age group at diagnosis was correlated with poor cancer survival in Japan.

The study included 3457 patients with bone sarcoma (1930 male and 1527 female) who were registered in the BSTT database from 2006 to 2013. Table 1 shows characteristics of bone sarcomas in AYAs by age at diagnosis and relevant clinical factors. The frequency of bone sarcoma occurrence was highest in AYA patients, who accounted for a marked proportion of patients with each type of sarcoma. Except for this, no categories were notably more or less prevalent in the AYA patient groups when compared with the same categories in other age groups. The majority of AYA had osteosarcoma 631 (56.2%), while 198 (17.6%) had chondrosarcoma. Among children, osteosarcoma was the most common 405 (77.7%), while 92 (17.7%) had Ewing sarcoma. Chondrosarcoma was the most common among adults 376 (38.3%), while 278 (28.3%) had osteosarcoma. Finally, among elderly, chondrosarcoma was the most common 303 (36.5%), while 183 (22.0%) had osteosarcoma. The incidences of osteosarcoma and Ewing sarcoma decreased with age, while the incidences of chondrosarcoma increased with age.

Figure 1a–d shows the cancer survival curves for patients with overall bone sarcoma (all types), as well as in those with osteosarcoma, chondrosarcoma, and Ewing sarcoma. There were no elderly patients with Ewing sarcoma. The cancer survival rate of AYA patients with osteosarcoma tended to be similar to that of children, but was better than those of adult and elderly patients. The cancer survival rate of AYA patients with chondrosarcoma tended to be similar to those of adults and was better than that of elderly patients. The cancer survival rates of children, AYA, and adult patients with Ewing sarcoma exhibited distinct tendencies, while the cancer survival rates of patients with Ewing sarcoma worsened with advancing age.

Table 2 shows the 5-year cancer survival statistics by age and sarcoma type. AYA patients with overall bone sarcoma did not exhibit worse cancer survival rates; however, the cancer survival was inversely correlated with age. The same tendencies were observed for each of osteosarcoma, chondrosarcoma, and Ewing sarcoma.

Table 3 shows univariate and multivariate analyses of prognostic factors of cancer survival by sarcoma type. Overall, the prognostic factors associated with poor cancer survival in patients with overall bone sarcoma were age ≥ 65 years (hazard ratio [HR]: 3.74; 95% confidence interval [CI]: 2.66–5.28; P < 0.001), high tumor grade (HR: 3.77; 95% CI: 1.93–7.37; P < 0.001), tumor size > 16 cm (HR: 2.20; 95% CI: 1.52–3.19; P < 0.001), and positive surgical margins (HR: 1.78; 95% CI: 1.21–2.62; P = 0.004) (Table 3).

The results of univariate and multivariate analysis of prognostic factors for cancer survival in patients with osteosarcoma are shown in Table 3. Upon multivariate analysis, the negative prognostic factors included age 40–64 years (HR: 1.58; 95% CI: 1.11–2.24; P < 0.001), age ≥ 65 years (HR: 3.26; 95% CI: 2.29–4.64; P < 0.001), tumor size > 16 cm (HR: 2.84; 95% CI: 1.86–4.35; P < 0.001), and tumor location on the trunk (HR: 2.64; 95% CI: 1.53–4.56; P < 0.001) (Table 3). AYA patients had a similar HR to children and did not exhibit an increased risk of tumor-related death compared with the other age groups.

Likewise, the prognostic factors associated with poor cancer survival in patients with chondrosarcoma were age ≥ 65 years (HR: 6.13; 95% CI: 2.38–15.75; P < 0.001), tumor size > 16 cm (HR: 3.06; 95% CI: 1.40–6.68; P = 0.005), and tumor location on the trunk (HR: 3.62; 95% CI: 1.08–12.15; P = 0.038) (Table 3). Being in the AYA age group did not increase the risk of tumor-related deaths compared with the child and adult groups; furthermore, the risk of tumor-related deaths in AYA patients was lower than that in the elderly group.

Lastly, the sole prognostic factor associated with poor cancer survival in patients with Ewing sarcoma was a positive surgical margin (HR: 5.28; 95% CI: 1.90–14.62; P = 0.001). AYA patients had an increased risk of tumor-related deaths compared with children (HR: 0.35; 95% CI: 0.15–0.83; P = 0.016), but not with adults. None of the patients with Ewing sarcoma in our study were ≥ 65 years of age (Table 3).

There have been fewer improvements in the clinical outcomes of AYA patients with cancer than for children and older adults, possibly because fewer studies focus on patients in this age group. Our study revealed the outcomes of AYA patients with bone sarcomas. We found that the AYA age group was not an independent poor prognostic factor for bone sarcoma overall, or for osteosarcoma, chondrosarcoma, or Ewing sarcoma individually. This was in contrast to other cancers, such as those of the breast and colon [17]. The cancer survival rate in AYA patients with bone sarcoma was similar to that of children and adults, and was more favorable than that of elderly patients. However, there have been no significant improvements in the overall 5-year survival rates for patients with bone sarcoma over the past few decades, unlike other cancers [10]. It is possible that this finding is the same in Japan. There have been significant improvements in the overall 5-year relative survival rates for patients with other cancers because of established effective chemotherapy and molecular targeted drugs [18, 19]. It is possible that AYA patients do not stand out because there have been no improvements in the overall 5-year relative survival rates for other age groups.

In addition, insurance rates are significantly lower in AYA patients [20]. AYA cancer survivors without health insurance do not receive cancer-related medical care, while those with insurance do [21]. In Japan, every Japanese person belongs to the public medical insurance that bears 70–90% of the treatment costs. Japan has a national bail out system for officially acknowledged people in need, which covers almost 100% of the actual treatment costs. It is possible that cancer survival rates of AYA patients did not differ from patients in other age groups because patients of all ages received equal medical treatment. To our knowledge, this study is the first to investigate bone sarcomas based on age groups, including AYAs, and their clinical outcomes [22, 23].

Previous epidemiological analyses conducted in Australia and the United States showed that the cancer survival rates of AYA patients with osteosarcoma were significantly worse than those of children [10, 11]. However, our study showed that Japanese AYA patients with osteosarcoma had cancer survival rates that were statistically equivalent to those in children. The standard chemotherapy for osteosarcoma is methotrexate, doxorubicin, and cisplatin (MAP). Although the use of chemotherapy children and AYA patients was high, it was infrequently used in adult patients (data not shown). This likely explains why the cancer survival rates of AYA patients with osteosarcoma were better than those in adult and elderly patients. One other possible reason is that in Japan, one of the inclusion criteria for many clinical trials regarding osteosarcoma is patients aged ≤40 years [24‐26]. AYA patients with osteosarcoma receive the same therapy as children. Tumor size is one of prognostic factors associated with poor survival among those with osteosarcoma [27]. In this study, there were few differences in the mean tumor size between AYA and adult patients (Additional file 1). Although children had the best osteosarcoma outcomes, the mean tumor size in children was the largest. For chondrosarcoma in particular, we found no other published studies with which to compare our results. The cancer survival rates of elderly patients with chondrosarcoma in our study were inferior to those of other age groups. One possible reason for this might be that elderly patients cannot be treated using surgery as a result of their advanced age. The proportions of patients who underwent surgery in the various age groups were as follows: children, 85.7%; AYA, 86.0%; adults, 87.1%; elderly, 73.1% (data not shown).

Tumor size is also a prognostic factor in Ewing sarcoma [28]. In this study, there were no significant differences in the mean tumor size between the age groups. One possible reason for this might be the distinct biological features of Ewing sarcoma in different age groups. It was reported that a gain in chromosome 1q and a loss in chromosome 16q were each associated with significantly worse outcomes; these mutations were more common in patients’ ≥15 years of age than in children [29]. Hence, the biology of Ewing sarcoma in AYA patients appears to be distinct from that in children [29]. In our study the frequency of Ewing sarcoma in AYA patients in Japan was lower than that in Australia and the United States [9, 11]. This is the reason why Caucasian populations are much more frequently affected, while there are low rates of the disease in East Asian and African populations [30].

The other independent risk factors for poor cancer survival in patients with bone sarcoma, as revealed in our study, are similar to those in previous studies of similar types of sarcoma. Consistent with our study, previous studies also reported that older age, large tumor size, high grade, and positive surgical margins were major factors that adversely influenced prognoses [28, 31‐33].

Our study had several limitations. First, the BSTT Registry was computerized in 2006, and no long-term observations of over 10-years were possible. Second, there were many patients for whom functional outcomes were not recorded in the BSTT Registry; these would have been useful to evaluate. Third, AYA cancer survivors experience adverse effects on their quality of life that persist beyond cancer diagnosis and treatment, including issues with infertility, body image, difficulty establishing relationships, and many other aspects of physical and social functioning [18]. There are no data with which to evaluate such parameters in the BSTT Registry. Forth, due to the extremely low incidence rate, the number of children with chondrosarcoma and elderly with Ewing sarcoma was insufficient. However, despite these limitations, our findings provide detailed information on the epidemiology of bone sarcoma among AYAs in Japan.

Our study is the first to provide data on the descriptive epidemiology and clinical outcomes of AYA patients with bone sarcomas using a nationwide, large-scale database. We found that, contrary to expectations, cancer survival rates of AYA patients with bone sarcomas were not inferior to those of other age groups in Japan.